Maleki Zahra, Canberk Sule, Field Andrew
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
IPATIMUP/Instituto de Investigação e Inovação Em Saúde (i3S), University of Porto, Porto, Portugal.
Cytopathology. 2025 Mar 26. doi: 10.1111/cyt.13479.
The World Health Organization Reporting System for Lung Cytopathology (WHO System) is an international effort aiming to serve patients worldwide in all medical resource settings and improve patient care globally. It is an evidence-based standardised reporting system applicable to all respiratory cytopathology specimens. The WHO System consists of five diagnostic categories including Insufficient/Inadequate/Non-diagnostic, Benign, Atypical, Suspicious for malignancy and Malignant. Each category has an associated risk of malignancy established from the current literature and recommendations for further management to establish as precise a diagnosis as possible. The key diagnostic cytopathological criteria for each entity are established, a differential diagnosis based on cytopathological features that is globally applicable is discussed, and best practices in appropriate ancillary studies are presented. The Insufficient/Inadequate/Non-diagnostic, Atypical and Suspicious for malignancy are diagnostic categories that are particularly challenging for cytopathologists and clinicians and patients due to the organ's diversity in sampling methods, cell types and the wide variety of neoplasms. Herein, we have reviewed the role of these three categories, discussed their definitions and cytopathological criteria, appropriate applications, risk of malignancy, clinical recommendations for patient's further diagnostic workup and application of ancillary studies. The aim was to increase cytopathologists and clinicians understanding of the three categories and provide a framework for the essential discussions that should follow.
世界卫生组织肺细胞病理学报告系统(WHO系统)是一项国际努力,旨在为全球所有医疗资源环境中的患者提供服务,并改善全球患者护理。它是一个基于证据的标准化报告系统,适用于所有呼吸道细胞病理学标本。WHO系统由五个诊断类别组成,包括不足/不充分/无法诊断、良性、非典型、疑似恶性和恶性。每个类别都有根据当前文献确定的相关恶性风险以及进一步管理的建议,以尽可能准确地做出诊断。确定了每个实体的关键诊断细胞病理学标准,讨论了基于全球适用的细胞病理学特征的鉴别诊断,并介绍了适当辅助研究的最佳实践。不足/不充分/无法诊断、非典型和疑似恶性是诊断类别,由于该器官在采样方法、细胞类型和多种肿瘤方面的多样性,对细胞病理学家、临床医生和患者来说尤其具有挑战性。在此,我们回顾了这三个类别的作用,讨论了它们的定义、细胞病理学标准、适当应用、恶性风险、患者进一步诊断检查的临床建议以及辅助研究的应用。目的是提高细胞病理学家和临床医生对这三个类别的理解,并为后续的重要讨论提供一个框架。